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Abstract
Oxidative stress has been implicated in the pathogenesis of diverse disease states, and may be a common
pathogenic mechanism underlying many major psychiatric disorders, as the brain has comparatively
greater vulnerability to oxidative damage. This review aims to examine the current evidence for the role of
oxidative stress in psychiatric disorders, and its academic and clinical implications. A literature search
was conducted using the Medline, Pubmed, PsycINFO, CINAHL PLUS, BIOSIS Previews, and Cochrane
databases, with a time-frame extending to September 2007. The broadest data for oxidative stress
mechanisms have been derived from studies conducted in schizophrenia, where evidence is available
from diﬀerent areas of oxidative research, including oxidative marker assays, psychopharmacology
studies, and clinical trials of antioxidants. For bipolar disorder and depression, a solid foundation for
oxidative stress hypotheses has been provided by biochemical, genetic, pharmacological, preclinical
therapeutic studies and one clinical trial. Oxidative pathophysiology in anxiety disorders is strongly
supported by animal models, and also by human biochemical data. Pilot studies have suggested eﬃcacy of
N-acetylcysteine in cocaine dependence, while early evidence is accumulating for oxidative mechanisms
in autism and attention deﬁcit hyperactivity disorder. In conclusion, multi-dimensional data support
the role of oxidative stress in diverse psychiatric disorders. These data not only suggest that oxidative
mechanisms may form unifying common pathogenic pathways in psychiatric disorders, but also intro-
duce new targets for the development of therapeutic interventions.
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Introduction
The aetiopathogenesis of psychiatric disorders is in-
completely understood, which may partly account for
the persisting dominance of the syndromic nosology
in psychiatry, despite its widely recognized inad-
equacies. An obstacle to the furthering of aetiological
understanding is the complex interplay of multitud-
inous variables, such that the precise delineation of
aetiology may be an unattainable goal. In this context,
a better understanding of fundamental pathophysio-
logical pathways and their interactions may provide a
broadly applicable conceptual framework and sub-
sequent means of therapeutic intervention. Biomedical
ﬁelds such as neurochemistry, psychoneuroendo-
crinology and psychoneuroimmunology are major
contributors in this respect, and neurochemistry, in
particular, informs most of the current biological treat-
ments. In a similar vein, oxidation biology is emerging
as a promising avenue of investigation, and has been
actively pursued in other areas of medicine (Barnham
et al., 2004; Mehta et al., 2006; Tsukahara, 2007).
The theory of oxidative stress as a pathophysio-
logical mechanism, at its most basic, can be explained
by the concept, sometimes referred to as the ‘oxygen
paradox’, that while oxygen is essential for aerobic
life, excessive amounts of its free radical metabolic
by-products are toxic (Davies, 1995). In brief, these
free radicals play integral roles in cellular signalling,
physiological immunological responses and mitosis.
However, being highly unstable molecules with un-
paired electrons, they have diﬀerential oxidative
strengths and hence potential to damage cellular pro-
teins, lipids, carbohydrates and nucleic acids (Filomeni
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and Ciriolo, 2006). Under physiological conditions,
multiple tiers of defence exist to protect against these
free radicals, including the restriction of their pro-
duction through the maintenance of a high oxygen
gradient between the ambient and cellular environ-
ments, their removal by non-enzymatic and enzymatic
antioxidants, and the reparation of oxidative damages
by structural repair and replacement mechanisms
(Davies, 2000; Sies, 1997). Despite the eﬃciency of this
multi-faceted defence network, a degree of oxidative
damage is inherent in aerobic life and is believed to
underlie the ageing process and inﬂuence organismic
lifespan (Finkel and Holbrook, 2000). Oxidative stress
occurs when redox homeostasis is tipped towards an
overbalance of free radicals, due to either their over-
production or deﬁciencies in antioxidant defence (Sies,
1997). The resultant cellular damage may range from
cellular structural damage and mitotic arrest, to
apoptosis and cell necrosis, depending on the level of
oxidative stress severity (Davies, 2000; Finkel and
Holbrook, 2000). The major classes of free radicals in
living organisms are the reactive oxygen species (ROS)
and the reactive nitrogen species (RNS), which are
respective collective terms for oxygen- and nitrogen-
derived radicals, as well as some non-radicals that
readily convert into radicals (Halliwell, 2006; Pacher
et al., 2007).
Oxidative stress mechanisms have been implicated
in the pathogenesis of psychiatric disorders. This hy-
pothesis has theoretical appeal, as the brain is con-
sidered particularly vulnerable to oxidative damage
for several reasons. These include its comparatively
high oxygen utilization and hence generation of free
radical by-products, its modest antioxidant defences,
its lipid-rich constitution that provides ready sub-
strates for oxidation, the reducing potential of certain
neurotransmitters, and the presence of redox-catalytic
metals such as iron and copper (Halliwell, 2006; Valko
et al., 2007). Additionally, the brain is also susceptible
to secondary and self-perpetuating damage from oxi-
dative cellular injury or necrosis, via the neurotoxic
eﬀects of released excitatory amines (mainly gluta-
mate) and iron, and the activated inﬂammatory
response (Halliwell, 2006). This intrinsic oxidative
vulnerability of the brain, together with the growing
evidence for neurodegenerative changes associated
with many psychiatric syndromes, suggest that oxi-
dative damage may be a plausible pathogenic candi-
date.
The focus of this review is on examining the evi-
dence for oxidative stress involvement in psychiatric
pathophysiology, and to comment on the therapeutic
and research implications of this knowledge.
Methods
A literature search was conducted using the Medline,
Pubmed, PsycINFO, CINAHL PLUS, BIOSIS Pre-
views, and Cochrane databases, up until September
2007. Search terms entered included: ‘oxidative, oxi-
dative stress, reactive species, reactive oxygen species,
reactive nitrogen species, antioxidants, lipid peroxi-
dation, thiobarbituric acid reactive substances, DNA
damage, psychiatry, pathogenesis, mental disorder,
schizophrenia, bipolar disorder, depression, anxiety
disorder, personality disorder, autism, attention deﬁcit
hyperactivity disorder, glutathione, N-acetylcysteine,
and treatment’, grouped in various combinations.
This was supplemented by a hand search of references
in selected articles, as well as references obtained from
researchers of oxidative mechanisms in the ﬁeld of
psychiatry. Some references from this latter source
have been published after the initial search date of
September 2007.
Results
Over the last decade, there has been a proliferation of
information on oxidative stress mechanisms in the
psychiatric literature (Figure 1). The largest and most
multi-faceted body of research exists for schizo-
phrenia, followed by bipolar disorder and depression.
A smaller collection of data has been published for
anxiety disorders, substance abuse, autism and atten-
tion deﬁcit hyperactivity disorder (ADHD). No studies
were found for personality disorder, and the search



























Figure 1. Estimated number of original research publications
on oxidation biology in core psychiatric disorders
(schizophrenia, bipolar disorder, major depressive
disorder, anxiety disorders) by year, as gauged by Medline
database search.
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Schizophrenia
The evidence behind oxidative stress mechanisms in
schizophrenia can be grouped into three categories:
ﬁrst, those studies that illustrate disturbed oxidative
homeostasis through oxidative enzyme genetic poly-
morphism and quantiﬁcation of antioxidants, free
radicals and markers of oxidative damage; second,
those demonstrating antioxidant mechanisms of es-
tablished antipsychotic drugs; third, those showing
beneﬁts from antioxidant therapies. These ﬁndings are
summarized in Table 1.
Markers of oxidative disturbances
Assays of oxidants and antioxidants
Most data demonstrating oxidative disturbances have
examined indirect measures of oxidative status, such
as peripheral and brain levels of antioxidants, oxidat-
ive enzymes and products. The direct measurement of
free radicals is hindered by their short half-lives and
low titres. Some studies have examined peripheral
concentrations of the free radical nitric oxide (NO)
in patients with schizophrenia by measuring its meta-
bolites, nitrites and nitrates, but have yielded incon-
sistent results. Whilst some have found elevated
plasma NO (Akyol et al., 2002; Li et al., 2006; Taneli
et al., 2004; Yanik et al., 2003; Zoroglu et al., 2002)
and reduced polymorphonucleocyte NO (Srivastava
et al., 2001) in those with schizophrenia compared
with controls, no signiﬁcant changes were found in
plasma and platelet NO (Srivastava et al., 2001).
Comparatively lower concentrations of the NO meta-
bolites were found in the cerebrospinal ﬂuid (CSF)
of schizophrenia patients (Ramirez et al., 2004) com-
pared with control patients who presented with non-
inﬂammatory and non-degenerative neurological
conditions, but these metabolites were signiﬁcantly
increased in a sample of post-mortem caudate speci-
mens (Yao et al., 2004). The disparate sample sizes,
patient characteristics, tissue specimen types and
substances measured in these studies, and the many
inherent metabolic variables in any given individual,
make direct comparison of these results diﬃcult,
although they support the presence of abnormal NO
metabolism in schizophrenia.
Similarly, studies involving blood assays of intrinsic
antioxidants have collectively demonstrated signiﬁ-
cantly altered antioxidant activities. Deﬁciency of
glutathione, the major intracellular antioxidant, in
its reduced form (GSH), has been observed and
suggested to be of pathophysiological signiﬁcance
in schizophrenia as early as 1934 (Looney and Childs,
1934), although diﬀerences did not reach statistical
signiﬁcance in that study. Signiﬁcant GSH deﬁciency
has subsequently been reported (Altuntas et al., 2000).
Reduced levels of the major antioxidant enzymes,
superoxide dismutase (SOD), catalase (CAT) and glu-
tathione peroxidase (GSH-Px), have also been found in
patients with schizophrenia compared with controls
(Ben Othmen et al., 2007; Li et al., 2006; Ranjekar et al.,
2003). Others have reported unchanged levels for
these three enzymes (Srivastava et al., 2001), or altered
concentrations of individual enzymes (Abdalla et al.,
1986; Akyol et al., 2002; Altuntas et al., 2000; Dietrich-
Muszalska et al., 2005; Herken et al., 2001; Kuloglu
et al., 2002c; Zhang et al., 2006a). A strong negative
correlation between blood GSH-Px and structural
measures of brain atrophy was also reported by an
early study (Buckman et al., 1987). Furthermore, some
studies have diﬀerentiated enzymatic changes among
the schizophrenia subtypes (Herken et al., 2001;
Zhang et al., 2006a), and one study showed a linear
correlation between antioxidant enzyme levels and
positive symptom severity (Li et al., 2006). The anti-
oxidants uric acid (Yao et al., 1998b), albumin and
bilirubin (Yao et al., 2000), and the plasma total anti-
oxidant status (TAS) (Yao et al., 1998a) have also been
reported to be lower in patients with schizophrenia
than in controls. Albumin, bilirubin and uric acid were
shown to be signiﬁcantly lower in neuroleptic-naive
patients with ﬁrst-episode schizophrenia, results that
were independent of smoking status (Reddy et al.,
2003), thus strengthening the evidence for defective
antioxidant defence as an early pathophysiological
change associated with the disease, rather than a
sequela of drug eﬀects, chronic disease and smoking.
Interestingly, the same study found no impairment of
antioxidative defence as determined using the same
indices, in those with ﬁrst-episode aﬀective psychosis
(Reddy et al., 2003), suggesting that oxidative stress
may be involved at diﬀerent stages in the two groups
of disorders.
In tandem with the peripheral antioxidant ab-
normalities found in patients with schizophrenia,
post-mortem brain tissue studies have reported sig-
niﬁcantly lower levels of glutathione in both its re-
duced (GSH) and oxidized forms (GSSG), and the two
enzymes responsible for conversions between these
two forms (GSH-Px, and glutathione reductase or GR),
in the caudate region from donors with schizophrenia
compared with those with other psychiatric conditions
and without psychiatric conditions. A concomitant
reduction in GSH:GSSG ratio, inverse correlations
between age and GSSG and between age and GR, as
well as the loss of normal correlations that exist in
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Table 1. Data relating to oxidative stress disturbances in schizophrenia
Compared
with controls Sample size (n) of patients
Markers of oxidative disturbances
Assays of oxidants and antioxidants
NO metabolites Plasma Increased 100 (Akyol et al., 2002) ; 82 (Zoroglu et al., 2002) ; 46 (Yanik et al., 2003) ; 20
(Taneli et al., 2004) ; 46 (Li et al., 2006)
Unchanged 62 (Srivastava et al., 2001)
PMN Decreased 62 (Srivastava et al., 2001)
Platelet Unchanged 62 (Srivastava et al., 2001)
CSF Decreased 10 (Ramirez et al., 2004)
PM brain Increased 18 (Yao et al., 2004)
Glutathione Erythrocyte Decreased 48 (Altuntas et al., 2000)
CSF Decreased 26 (Do et al., 2000)
MRS Decreased 14 (Do et al., 2000)
PM brain Decreased 12 (Yao et al., 2006a)
Antioxidative
enzymes
SOD Plasma Decreased 100 (Akyol et al., 2002) ; 92 (Zhang et al., 2006a)
Erythrocyte Increased 50 (Abdalla et al., 1986) ; 48 (Altuntas et al., 2000) ; 25 (Kuloglu et al., 2002c)
Unchanged 65 (Herken et al., 2001)
Decreased 31 (Ranjekar et al., 2003) ; 46 (Li et al., 2006) ; 60 (Ben Othmen et al., 2007)
PMN Unchanged 62 (Srivastava et al., 2001)
Platelet Decreased 36 (Dietrich-Muszalska et al., 2005)
PM brain Increased 13 (Michel et al., 2004)
CAT Erythrocyte Increased 65 (Herken et al., 2001)
Decreased 31 (Ranjekar et al., 2003) ; 46 (Li et al., 2006) ; 60 (Ben Othmen et al., 2007)
PMN Unchanged 62 (Srivastava et al., 2001)
GSH-Px Erythrocyte Increased 39 (Herken et al., 2001) ; 25 (Kuloglu et al., 2002c)
Unchanged 50 (Abdalla et al., 1986)
Decreased 48 (Altuntas et al., 2000) ; 31 (Ranjekar et al., 2003) ; 46 (Li et al., 2006) ; 60
(Ben Othmen et al., 2007)
PMN Unchanged 62 (Srivastava et al., 2001)
Plasma Unchanged 100 (Akyol et al., 2002)
Decreased 92 (Zhang et al., 2006a)
PM brain Decreased 12 (Yao et al., 2006a)
Uric acid Plasma Decreased 82 (Yao et al., 1998b)
Albumin, bilirubin Plasma Decreased 81 (Yao et al., 2000)
Total antioxidant status Plasma Decreased 45 (Yao et al., 1998a)
Assays of oxidative products
TBARS/MDA Plasma Increased 26 (Mahadik et al., 1998) ; 100 (Akyol et al., 2002) ; 25 (Kuloglu et al., 2002c) ; 92 (Zhang
et al., 2006a) ; 47 (Dietrich-Muszalska and Olas, 2007) ; 60 (Ben Othmen et al., 2007)
Unchanged 31 (Ranjekar et al., 2003)
Erythrocyte Increased 48 (Altuntas et al., 2000) ; 65 (Herken et al., 2001)
PMN Unchanged 62 (Srivastava et al., 2001)
Platelet Increased 36 (Dietrich-Muszalska et al., 2005)








Isoprostanes Urine Increased 47 (Dietrich-Muszalska and Olas, 2007)
DNA damage PM brain Increased 10 (Nishioka and Arnold, 2004)
Lymphocyte Unchanged 20 (Psimadas et al., 2004) ; 16 (Young et al., 2007)
Molecular and genetic studies
Molecular studies Altered proteins, RNA and metabolites relating to
mitochondrial function and oxidative stress pathways
10, 54 (Prabakaran et al., 2004)
Susceptibility genes Glutamate cysteine ligase modiﬁer (GCLM) subunit Multiple studies (Tosic et al., 2006)
Glutamate cysteine ligase catalytic (GCLC) subunit 388 (Gysin et al., 2007)
Manganese-SOD (-9Ala allele) 153 (Akyol et al., 2005)
Glutathione S-transferase T1 (GSTT1) 292 (Saadat et al., 2007)
ND4 subunit of NADH-ubiquinone reductase 181 (Marchbanks et al., 2003)
Antioxidant properties of antipsychotics
Clinical studies Improvement of antioxidants¡MDA
disturbances with treatment
41 (Zhang et al., 2003) ; 16 (Evans et al., 2003) ; 48 (Dakhale et al., 2004)
No reversal of oxidants, antioxidants¡MDA with treatment 20 (Taneli et al., 2004) ; 40 (Sarandol et al., 2007a)
Preclinical studies Rats Reversal of haloperidol-
induced oxidative stress
Clozapine, olanzapine, risperidone (Pillai et al., 2007)
In-vitro cell studies Reversal of induced
oxidative stress
Olanzapine (Wei et al., 2003) ; clozapine, olanzapine, quetiapine,
risperidone (Wang et al., 2005)
Antioxidant therapies
Trial design Treatment outcomes Sample size (n)
Vitamins C & E RCT; 8 wk; vitamin C vs. placebo adjunctive to
antipsychotic treatment
Reversal of MDA and ascorbic acid levels ; superior BPRS
outcomes
40 (Dakhale et al., 2005)
Open-labelled; 4 months; adjunctive omega-3-fatty
acids and vitamins C/E supplements
Symptomatic improvement ; no signiﬁcant change in TBARS 33 (Arvindakshan et al., 2003a)
Improved positive and negative symptoms, extrapyramidal
side-eﬀects, SOD levels compared with baseline
17 (Sivrioglu et al., 2007)
Open-labelled; 2 wk; ascorbic acid adjunctive
to haloperidol
No symptomatic improvement 8 (Straw et al., 1989)
Ginkgo biloba extract RCT; 12 wk; EGb vs. placebo adjunctive to haloperidol Higher response rate; lower SAPS and SANS scores ;
reversal of SOD levels
109 (Zhang et al., 2001a,b)
Single-blinded randomized trial ; 8 wk; EGb plus
olanzapine vs. olanzapine alone
Lower SAPS scores ; reversal of SOD and CAT levels 29 (Atmaca et al., 2005)
NAC RCT; 6 months ; NAC vs. placebo adjunctive to
antipsychotic treatment
Superior outcomes on CGI, PANSS, BAS 140 (Berk et al., unpublished
observations)
BAS, Barnes Akathisia Scale ; BPRS, Brief Psychiatric Rating Scale ; CAT, catalase ; CGI, Clinical Global Impressions ; CSF, cerebrospinal ﬂuid; EGb, Ginkgo biloba extract ; GSH-Px,
glutathione peroxidase ; MDA, malondialdehyde; MRS, magnetic resonance spectroscopy; NAC, N-acetylcysteine ; NO, nitric oxide; PANSS, Positive and Negative Symptoms Scale ;
PM, post-mortem; PMN, polymorphonucleocyte ; RCT, randomized controlled trial ; RNA, ribonucleic acid; SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the








dynamic equilibrium, were also identiﬁed in the
schizophrenia group (Yao et al., 2006a). Together,
these ﬁndings indicate the presence of disturbed
redox coupling mechanisms in schizophrenia, which
may be related to GSH deﬁciency and/or time-related
reductions in GSSG and GR activities (Yao et al.,
2006a). Another post-mortem study examined a num-
ber of cortical and subcortical areas from donors
with schizophrenia and controls, and found elevated
levels of two SOD isoenzymes in the frontal cortex and
substantia innominata of those with schizophrenia,
thereby suggesting neuroanatomical speciﬁcity of
redox disturbances in schizophrenia (Michel et al.,
2004). Further supportive evidence is provided by a
study reporting a 27% reduction in the CSF glutathione
level in neuroleptic-naive patients with schizophrenia
compared with controls, which coexisted with a 52%
glutathione reduction in the medial prefrontal cortex,
as measured by magnetic resonance spectroscopy (Do
et al., 2000). The low CSF glutathione appears to be
consistent with previous ﬁndings of decreased levels
of its metabolite, c-glutamylglutamine, in the CSF of
schizophrenia patients (Do et al., 1995).
Assays of oxidative products
Estimating levels of oxidative reactive products pro-
vide another useful strategy to determine the impact
of oxidative stress. Published studies have predomi-
nantly examined products of lipid peroxidation
and DNA oxidation as markers of oxidative damage.
A widely used method of measuring lipid peroxi-
dation is the performance of thiobarbituric acid
reactive substances (TBARS) assays. TBARS are low-
molecular-weight substances, consisting largely of
malondialdehyde (MDA), which are formed from the
decomposition of unstable lipid peroxidation products
and react with thiobarbituric acid to form ﬂuorescent
adducts (Fukunaga et al., 1998). TBARS have been
reported to be elevated in the plasma (Akyol et al.,
2002; Dietrich-Muszalska and Olas, 2007; Kuloglu
et al., 2002c; Mahadik et al., 1998; Ranjekar et al., 2003;
Zhang et al., 2006a), erythrocytes (Altuntas et al., 2000;
Herken et al., 2001), leucocytes (Srivastava et al.,
2001) and platelets (Dietrich-Muszalska et al., 2005)
of schizophrenia patients, in conjunction with abnor-
malities in antioxidant levels, and depleted essential
polyunsaturated fatty acids,which are especially prone
to lipid peroxidation (Arvindakshan et al., 2003b;
Khan et al., 2002). Data on CSF levels of TBARS in
schizophrenia are limited, but one small study has
been published, reporting reduced levels in a group
of actively psychotic patients compared with controls
(Skinner et al., 2005). This unexpected ﬁnding raises
questions about the origins of the elevated blood
TBARS that has been broadly reported in the litera-
ture, although the CSF results may have been
confounded by diminished neuronal membrane sub-
strates in the patient cohort (Skinner et al., 2005) and
replication of the study is required. The F2 iso-
prostanes, products of the free radical-induced oxi-
dation of arachidonic acid, have been suggested to
be superior to TBARS as markers of lipid peroxidation,
and a marked increase of urinary 8-isoprostaglandin
F2a has recently been reported in a sample of schizo-
phrenia patients compared with healthy controls
(Dietrich-Muszalska and Olas, 2007).
A smaller collection of studies has been published
in relation to markers of DNA damage in schizo-
phrenia. A post-mortem study examining the hippo-
campi of patients with ‘poor outcome’ schizophrenia
and non-psychiatric controls, found a ten-fold higher
presence of neuronal 8-hydroxy-2’-deoxyguanosine
(8-OhdG) among the patients compared with controls,
which correlatedwith elevated quantities of a cell-cycle
activation marker (Ki-67) (Nishioka and Arnold, 2004).
One study reported a trend increase in lymphocyte
DNA damage in schizophrenia patients compared
with control subjects (Young et al., 2007), but another
found no diﬀerence, although those with schizo-
phrenia showed a non-signiﬁcant increase in sensi-
tivity to externally inducedDNAdamage and decrease
in DNA repair eﬃciency (Psimadas et al., 2004).
Molecular and genetic studies
Evidence from molecular and genetic studies support
fundamental redox disturbances in the aetiopatho-
genesis of schizophrenia. In an integrative study of
post-mortem prefrontal cortex, using a parallel trans-
criptomics, proteomics and metabolomics approach,
a large proportion of alterations on the transcript,
protein and metabolite levels were demonstrated to be
associated with mitochondrial function, energy meta-
bolism and oxidative stress responses. Furthermore,
almost 90% of schizophrenia patients could be dif-
ferentiated from controls in this study, including
neuroleptic-naive patients and those with <1 yr of
overt illness, based on a set of genes that encode for
mitochondrial complexes and redox-sensing proteins
(Prabakaran et al., 2004). This provides persuasive
evidence that mitochondrial function and oxidative
stress pathways are intrinsically involved in the patho-
genesis of the disorder, although the exact nature of
their roles, in particular whether they are primary or
secondary changes, are yet to be clariﬁed.
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Other studies have identiﬁed links between schizo-
phrenia and speciﬁc genes, such as those for the key
glutathione-synthesizing enzyme, glutamate cysteine
ligase modiﬁer (GCLM) subunit (Tosic et al., 2006),
and for the antioxidant enzymes manganese super-
oxide dismutase (Mn-SOD) (Akyol et al., 2005) and
glutathione S-transferase T1 (GSTT1) (Saadat et al.,
2007). The glutamate cysteine ligase (GCL) connection
seems particularly promising, in view of recent data
indicating reduced GCL activity, decreased expression
of its catalytic subunit (GCLC), and GCLC poly-
morphism in those with schizophrenia (Gysin et al.,
2007). A mitochondrial DNA sequence variation
aﬀecting a subunit of NADH-ubiquinone reductase
(Complex I), a component of the electron transport
chain responsible for generating superoxide, has also
been associated with schizophrenia patients and with
increased superoxide levels in post-mortem brain
samples (Marchbanks et al., 2003). On a related sub-
ject, polymorphism of the glutathione S-transferase
pi gene (GSTP1) has been reported to be associated
with vulnerability to develop psychosis in the setting
of methamphetamine abuse (Hashimoto et al., 2005),
which may have some bearing on schizophrenia.
Antioxidant properties of antipsychotics
Clinical studies
Antioxidant eﬀects of established antipsychotic agents
provide indirect evidence for oxidative pathophysio-
logical mechanisms in schizophrenia. Abnormalities in
levels of antioxidants and oxidative products have
been reported to reverse over the course of treatment
with atypical antipsychotics, coinciding with sympto-
matic improvement (Dakhale et al., 2004; Zhang et al.,
2003). In two published studies, baseline serum SOD
(Dakhale et al., 2004; Zhang et al., 2003), MDA and
ascorbic acid (Dakhale et al., 2004) levels in patients
with schizophrenia signiﬁcantly diﬀered from those in
age- and sex-matched controls, taking smoking status
into consideration. Within the patient groups, their
baseline levels signiﬁcantly shifted towards normality
after treatment with atypical antipsychotics over the
study durations of 8 wk (Dakhale et al., 2004) and
12 wk (Zhang et al., 2003), respectively. Another study
with a smaller sample size conducted over 6 months
likewise showed normalization of the antioxidative
enzymes SOD, CAT and GSH-Px with treatment
(Evans et al., 2003). These oxidative marker changes
correlated with symptomatic improvements as
measured by validated scales, further substantiating
an intrinsic link between oxidative stress status and
psychotic symptomatology. In contrast, others did not
ﬁnd signiﬁcant changes in a number of oxidative-
antioxidative parameters (Sarandol et al., 2007a) or in
serum NO metabolites (Taneli et al., 2004). Membrane
essential polyunsaturated fatty acids (EPUFAs)
depletion has been reported in schizophrenia, with
one proposed mechanism being oxidative peroxi-
dation (Evans et al., 2003; Khan et al., 2002; Ranjekar
et al., 2003). Data showing repletion of EPUFAs with
treatment (Evans et al., 2003) and higher levels of
EPUFAs in medicated patients with chronic schizo-
phrenia compared with never-medicated ﬁrst-episode
patients (Khan et al., 2002), although inconclusive,
suggest an ameliorating eﬀect of antipsychotics on
disease-related oxidative stress status.
A diﬀerential impact on oxidative stress status may
exist between typical and atypical antipsychotic medi-
cations. Higher levels of lipid peroxidation products
have been reported in patients treated with typical
than atypical drugs (Kropp et al., 2005), but contra-
dictory results were reported by others (Gama et al.,
2006; Zhang et al., 2006a). The diﬀering pro-oxidant
potentials of the antipsychotics have been postulated
as a mediating factor in the more common develop-
ment of tardive dyskinesia with typical agents
(Andreassen and Jorgensen, 2000).
Preclinical studies
Animal data have demonstrated elevated oxidative
stress markers with 45-d and 90-d administration of
haloperidol, but not atypicals (Parikh et al., 2003). In
extending this study in rats to 180 d, haloperidol was
again associated with the greatest level of oxidative
stress, but oxidative stress as gauged by signiﬁcant
reductions in enzymatic activities were also seen with
chlorpromazine and the atypical agents ziprasidone,
risperidone and olanzapine. Both typical and atypical
agents were associated with increased lipid peroxi-
dation after 180 d, except for olanzapine. In addition,
clozapine, olanzapine, and to a lesser extent risper-
idone, were able to reverse the changes induced by
haloperidol (Pillai et al., 2007). Haloperidol-induced
oxidative stress parameters in rats have also been
shown to be ameliorated by the antioxidant drug, N-
acetylcysteine (NAC) (Harvey et al., 2007). In-vitro
cell studies have demonstrated a protective eﬀect of
atypicals, such as olanzapine and quetiapine, on PC12
cells exposed to oxidative stress (Wang et al., 2005;
Wei et al., 2003).
Antioxidant therapies
Clinical trials investigating adjunctive antioxidants
in the treatment of schizophrenia have utilized
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vitamins C and E, Ginkgo biloba extract (EGb), and
NAC.
Vitamins C and E
The vast majority of vitamin E studies in schizo-
phrenia has focused on its preventive and therapeutic
roles in tardive dyskinesia. Conﬂicting results have
been found for dyskinetic symptoms (Adler et al., 1998,
1999), but some have reported eﬃcacy in psycho-
pathology (Lohr and Caligiuri, 1996). A small (n=40)
randomized, controlled trial comparing vitamin C and
atypical antipsychotics with atypical antipsychotics
alone (placebo) found that at the end of 8 wk, the
baseline plasma ascorbic acid and MDA abnormalities
had been signiﬁcantly reversed in the vitamin C group
compared with the placebo group. Symptomatic out-
come, as measured with the Brief Psychiatric Rating
Scale (BPRS), was also signiﬁcantly better for the
vitamin C group (Dakhale et al., 2005). Other studies
reported positive treatment outcomes, in terms of
symptoms, functioning and extrapyramidal side-
eﬀects, with the supplementation of a combination
of omega-3-fatty acids and vitamins C and E
(Arvindakshan et al., 2003a; Sivrioglu et al., 2007).
However, these ﬁndings are diﬃcult to interpret
in view of the small sample sizes (n=17 and n=33),
the studies’ open-label and non-randomized designs,
and concomitant use of antioxidants and poly-
unsaturated fatty acids. Lack of eﬃcacy was reported
by a small (n=8), 2-wk open-label trial of vitamin C
(Straw et al., 1989).
Ginkgo biloba extract
A small body of literature has suggested eﬃcacy
of supplementary EGb in schizophrenia. In a 12-wk,
double-blind, randomized trial comparing EGb and
placebo adjunctive to haloperidol in treatment-
resistant patients with schizophrenia (n=109), those
treated with EGb showed superior outcomes as
measured by a higher response rate (57.1% vs. 37.7%)
and signiﬁcant score reductions on the Scale for the
Assessment of Positive Symptoms (SAPS) and Scale
for the Assessment of Negative Symptoms (SANS).
Scores on these scales did not signiﬁcantly vary in the
placebo group, although both groups improved on
BPRS scores. Furthermore, treatment-emergent behav-
ioural and neurological side-eﬀects were signiﬁcantly
lower in the EGb group (Zhang et al., 2001b). This
group also showed superior improvements in peri-
pheral T cell subsets (CD3+, CD4+, CD8+ and IL-2-
secreting cells), which were diminished at baseline
(Zhang et al., 2006b). These authors additionally
reported elevated pre-treatment SOD levels among
patients with treatment-resistant schizophrenia,
correlating with positive symptomatic severity, which
was selectively reduced in patients receiving EGb but
not placebo (Zhang et al., 2001a, 2006b; Zhou et al.,
1999), thereby suggesting that antioxidant activity,
schizophrenia symptoms and peripheral immune
functions may be interrelated. A confounder in this
group of studies is the use of haloperidol as treatment
base, which through its potential in inducing oxidative
stress and cognitive blunting, may have added iatro-
genic complexities to the disease and treatment pro-
cess, such that it is diﬃcult to determine whether
the superior outcomes were due to lessened adverse
eﬀects, underlying psychopathology, or both. This
concern was minimized in a subsequent placebo-
controlled trial of EGb adjunctive to olanzapine,
which also found signiﬁcantly lower SAPS scores,
SOD and CAT levels among the EGb group, although
this study had other limitations, such as its single-
blinded design and underpowered sample size
(n=29) (Atmaca et al., 2005).
N-acetylcysteine
NAC is a cysteine prodrug with high bioavailability,
which is thought to exert antioxidative eﬀects primar-
ily through enhancing stores of the major intracellular
antioxidant, glutathione, by stimulating its formation
from cysteine (Atkuri et al., 2007). A series of experi-
ments using an animal model has demonstrated that
the pharmacodynamic actions of NAC involve the
cystine-glutamate antiporter and extrasynaptic group
II metabotropic glutamate receptors (mGluR) (Baker
et al., 2007). This may have particular relevance in
schizophrenia, as glutamatergic dysfunction has been
implicated as a pathophysiological pathway (Goﬀ and
Coyle, 2001).
NAC has been studied as an adjunctive treatment
in schizophrenia in a recently completed 6-month,
double-blind, randomized, placebo-controlled trial
(n=140), which found signiﬁcant advantages of NAC
over placebo on several scales that include the Clinical
Global Impressions (CGI) (eﬀect size of 0.43), the
Positive and Negative Symptoms Scale (PANSS) (ef-
fect size of 0.57) and the Barnes Akathisia Scale (BAS)
(eﬀect size of 0.44) (Berk et al., unpublished obser-
vations). In a subset of patients enrolled in this study
(n=11), NAC was also associated with an increase in
plasma glutathione and the amelioration of mismatch
negativity, an auditory evoked potential component
characteristically impaired in schizophrenia, which
may indicate the ability of NAC to correct more
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fundamental neurophysiological dysfunction (Lavoie
et al., 2007).
Bipolar disorder
Similar types of studies, albeit more limited in scope,
have provided evidence for oxidative dysfunction in
bipolar disorder (Table 2). The majority is derived
from biochemical and pharmacological data.
Markers of oxidative disturbances
Oxidative disturbances have been demonstrated in
both animal models and human studies.
Animal studies
In animal models of mania, where amphetamine was
administered to rats, raised levels of protein oxidation
markers were detected in brain tissues following both
single and repeated dosing, with the additional in-
duction of lipid peroxidation markers on repeated ex-
posure (Frey et al., 2006a). Exposure to amphetamine
has also been linked to SOD and CAT alterations (Frey
et al., 2006c), as well as to increased superoxide pro-
duction in submitochondrial particles in the rat brain
(Frey et al., 2006b). In these studies, the striatum,
hippocampus and prefrontal cortex have shown dif-
ferential vulnerability and adaptivity (Frey et al.,
2006a, c).
Human assays of oxidants, antioxidants and oxidative
products
Human data of oxidative markers in bipolar disorder
are often derived from studies with patient samples
that include other psychiatric disorders. In two such
studies, increased SOD activities as compared with
healthy controls were associated with both bipolar
disorder and schizophrenia (Abdalla et al., 1986;
Kuloglu et al., 2002c), whereas another study found
a trend for reduced SOD in bipolar disorder and sig-
niﬁcantly reduced CAT levels for both groups
(Ranjekar et al., 2003). However, GSH-Px changes
were reported for schizophrenia only (Kuloglu et al.,
2002c; Ranjekar et al., 2003). An increase in the lipid
peroxidation product, TBARS, was also reported for
both bipolar disorder and schizophrenia (Kuloglu
et al., 2002c), as was a decrease in EPUFAs (Ranjekar
et al., 2003). In a study involving patients with bipolar
disorder, major depressive disorder and schizoaﬀec-
tive disorder, the pooled data showed reduced NO,
CAT and GSH-Px levels, unchanged SOD and elevated
MDA levels compared with controls, but the results
were not analysed according to diagnosis (Ozcan et al.,
2004).
A comparatively large study was conducted solely
on bipolar disorder patients, who were at various
phases of the illness, thus allowing the exploration of
phase-speciﬁc changes in oxidative stress status.
Interestingly, raised TBARS levels were observed re-
gardless of illness phase, whereas GSH-Px activity was
only elevated in euthymia but not in depressed or
manic phases. Increased SOD activity was associated
with manic and depressive episodes but not euthymia,
and CAT reduction with mania and euthymia but
not depression (Andreazza et al., 2007). An oxidative
proﬁle consistent with these ﬁndings were reported in
a twin case report of mania (Frey et al., 2007).
However, another study reported lowered SOD levels
in bipolar depression, in conjunction with elevated
NO levels (Selek et al., 2007). In a study comparing
both unmedicated and lithium-treated patients in
manic episodes with healthy controls, TBARS, SOD
and CAT levels were signiﬁcantly higher in manic
patients compared with controls, with the lithium-
treated group showing lower levels of TBARS and
SOD than unmedicated patients, suggesting possible
corrective eﬀects of lithium on oxidative parameters
(Machado-Vieira et al., 2007). Elevated NO and nitrite
levels have been reported in bipolar disorder patients
(Gergerlioglu et al., 2007; Savas et al., 2006; Yanik et al.,
2004b), and have been correlated with the number of
manic episodes (Gergerlioglu et al., 2007; Savas et al.,
2006).
Molecular and genetic studies
Genetic studies have identiﬁed certain polymorphisms
in bipolar disorder patients that play a role in oxidat-
ive homeostasis. A single-nucleotide polymorphism
of the TRPM2 gene, which encodes for a calcium
channel receptor, has been strongly associated with
bipolar disorder and is understood to cause cellular
calcium dysregulation in response to oxidative stress
(McQuillin et al., 2006). Dysregulation of second-
messenger calcium has been described in bipolar dis-
order, and the modulation of this is thought to be a
therapeutic mediating mechanism of lithium (Berk
et al., 1995, 1996). Innate dysregulation of the
apoptosis and oxidative processes has been suggested
by a recent study, in which the hippocampal ex-
pression of genes encoding DNA repair and anti-
oxidant enzymes were found to be down-regulated in
bipolar disorder, while many apoptosis genes were
up-regulated (Benes et al., 2006).
A related theoretical framework for the patho-
physiology of bipolar disorder has centred on impaired
mitochondrial metabolism as the primary defect in
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Table 2. Data relating to oxidative stress disturbances in bipolar disorder
Compared
with controls Sample size (n) of patients
Markers of oxidative disturbances
Assays of oxidants and antioxidants
NO metabolites Serum Increased 43 (Yanik et al., 2004b); 27 (euthymia) (Savas et al.,
2006); 30 (depressed phase) (Selek et al., 2007) ;
29 (manic phase) (Gergerlioglu et al., 2007)
Erythrocyte Decreased 30 (18 bipolar disorder; 12 other aﬀective
disorders) (Ozcan et al., 2004)
Antioxidative
enzymes
SOD Plasma or serum Increased 27 (euthymia) (Savas et al., 2006); 84 (manic and
depressed phases only) (Andreazza et al., 2007);
45 (manic phase) (Machado-Vieira et al., 2007)
Decreased 30 (depressed phase) (Selek et al., 2007); 29
(manic phase) (Gergerlioglu et al., 2007)
Erythrocyte Increased 20 (Abdalla et al., 1986); 23 (Kuloglu et al., 2002c)
Unchanged 10 (Ranjekar et al., 2003); 30 (18 bipolar disorder;
12 other aﬀective disorders) (Ozcan et al., 2004)
CAT Plasma or serum Increased 45 (manic phase) (Machado-Vieira et al., 2007)
Decreased 84 (manic phase and euthymia only) (Andreazza
et al., 2007)
Erythrocyte Decreased 10 (Ranjekar et al., 2003); 30 (18 bipolar disorder;
12 other aﬀective disorders) (Ozcan et al., 2004)
GSH-Px Serum Increased 84 (euthymia only) (Andreazza et al., 2007)
Erythrocyte Unchanged 20 (Abdalla et al., 1986); 23 (Kuloglu et al., 2002c);
10 (Ranjekar et al., 2003)
Decreased 30 (18 bipolar disorder; 12 other aﬀective
disorders) (Ozcan et al., 2004)
Assays of oxidative products
TBARS/MDA Plasma or serum Increased 23 (Kuloglu et al., 2002c); 84 (Andreazza et al.,
2007); 45 (manic phase) (Machado-Vieira et al.,
2007)
Unchanged 10 (Ranjekar et al., 2003)
Erythrocyte Increased 30 (18 bipolar disorder; 12 other aﬀective
disorders) (Ozcan et al., 2004)
Molecular and genetic studies
Susceptibility genes TRPM2 600 (McQuillin et al., 2006)
Increased expression of neuronal NOS1, altered
expression of GSH-Px 4, glyoxylase, esterase
D-formylglutathione hydrolase, glutathione
synthetase, glutathione S-transferase A2,
M5 and omega, CAT, SOD
9 (Benes et al., 2006)
Antioxidant properties of established therapeutic agents
Clinical studies Improvement of lowered SOD but no signiﬁcant
change in NO elevation with treatment in manic
patients
29 (Gergerlioglu et al., 2007)
Improvement of reduced GSH-Px with treatment 30 (18 bipolar disorder; 12 other aﬀective
disorders) (Ozcan et al., 2004)
Improvement of elevated SOD and TBARS in
the twin treated for mania compared with the
other twin who refused anti-manic treatment
Monozygotic twin case study (Frey et al., 2007)
Rise in blood GSH 2–4 h after ECT 20 (mixed diagnoses) (Henneman and
Altschule, 1951)
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bipolar disorder (Kato, 2006; Young, 2007). This con-
cept is supported by data from a number of sources,
including magnetic resonance spectroscopy evidence
of decreased brain energy metabolism, maternal
hereditary patterns, comorbid mitochondrial diseases,
mitochondrial mechanisms of mood stabilisers, and
mitochondrial DNA deletions, mutations and poly-
morphisms (Kato, 2007).
Antioxidant properties of established therapeutic
agents
Clinical studies
Indirect support for the pathophysiological role of
oxidative stress in bipolar disorder comes from clinical
studies that demonstrate normalisation of oxidative
parameters over the course of treatment (Frey et al.,
2007; Gergerlioglu et al., 2007; Henneman and
Altschule, 1951; Ozcan et al., 2004). This has been el-
egantly illustrated by a case report of twins presenting
with mania, where increased TBARS, SOD and DNA
damage, and decreased CAT were observed in both
patients prior to treatment. Whilst the twin who was
successfully treated showed normalization of TBARS
and SOD, the oxidative parameters remained un-
changed for the other twin who refused treatment and
continued to be manic (Frey et al., 2007). In addition,
the evidence behind the antioxidant properties of
antipsychotics is also relevant for bipolar disorder,
considering their eﬃcacy in its treatment, particularly
of mania. An early study of psychiatric patients, in-
cluding those with bipolar disorder, also bears some
relevance to the current discussion through demon-
strating a rise in blood glutathione 2–4 h following
electroconvulsive therapy (Henneman and Altschule,
1951).
Preclinical studies
The antioxidant properties of mood stabilisers have





Rats Prevention/reversal of lipid
peroxidation in rat model of mania
Lithium, valproate (Frey et al., 2006d)
Lithium increased total antioxidant
reactivity, increased SOD, and reduced
ROS formation; unable to prevent
stress-induced disturbances in
oxidative parameters




Inhibited ferric chloride-induced lipid
peroxidation and protein oxidation
Valproate (Wang et al., 2003)
Inhibited glutamate-induced MDA,
protein carbonyls, DNA fragmentation
and cell death
Lithium, valproate (Shao et al., 2005)
Inhibited hydrogen peroxide-induced
cell death; increased GSH and
GCL expression
Lithium, valproate, carbamazepine,
lamotrigine (Cui et al., 2007)
Cytoprotective eﬀects against hydrogen
peroxide-induced neural cell death
Lithium, valproate (Lai et al., 2006)
Antioxidant therapies
Trial design Treatment outcomes Sample size (n)
NAC RCT; 6 months; NAC vs. placebo
adjunctive to treatment-as-usual
Superior outcomes on BDRS, MADRS
and functional measures
75 (Berk, 2007)
BDRS, Bipolar Depression Rating Scale; CAT, catalase; ECT, electroconvulsive therapy; GCL, glutamate cysteine ligase;
GSH, reduced glutathione; GSH-Px, glutathione peroxidase; MADRS, Montgomery–A˚sberg Depression Rating Scale; MDA,
malondialdehyde; NAC, N-acetylcysteine; NOS1, nitric oxide synthase; ROS, reactive oxygen species; SOD, superoxide
dismutase; TBARS, thiobarbituric acid reactive substances.
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and cell studies. In a rat model of mania using am-
phetamine, both lithium and valproate were able to
prevent and reverse amphetamine-induced hyper-
activity, prevent lipid peroxidation in the hippocam-
pus and reverse lipid peroxidation in the prefrontal
cortex. No alterations were seen for protein carbonyl
formation in this model, and changes in antioxidant
enzymes were variable (Frey et al., 2006d). Others
have supported the antioxidant eﬀects of lithium, but
have not found it able to prevent stress-induced oxi-
dative damage in rats (de Vasconcellos et al., 2006).
Treatment with valproate has been shown to inhibit
lipid peroxidation and protein oxidation in primary
cultured rat cerebrocortical cells exposed to an oxidant
(Wang et al., 2003). Using similar cell cultures, treat-
ment with lithium or valproate was also shown to in-
hibit the glutamate-induced intracellular calcium
release, lipid peroxidation, protein oxidation, DNA
fragmentation and cell death (Shao et al., 2005). Other
cell culture studies have associated lithium and
valproate with increased expression of the endoplas-
mic reticulum stress proteins GRP78, GRP94 and cal-
reticulin (Chen et al., 2000; Shao et al., 2006), increased
levels of the anti-apoptotic factor bcl-2 (Chen et al.,
1999), glutathione and glutamate-cysteine ligase (Cui
et al., 2007), and reduced cytochrome c release and
caspase-2 activation (Lai et al., 2006), thereby implying
that multiple pharmacodynamic actions may underlie
the neuroprotective eﬀects of these agents against
oxidative stress. However, increased glutathione levels
and glutamate-cysteine ligase gene expression found
with other mood stabilizers such as carbamazepine
and lamotrigine suggest that glutathione may be a
common neuroprotective target among mood stabi-
lizers (Cui et al., 2007). Furthermore, evidence from
human cell studies have found neuroprotective eﬀects
from lithium and valproate in neural but not glial cells




A recent randomized, placebo-controlled trial of
adjunctive NAC in the treatment of bipolar disorder
(n=75) has shown favourable outcomes, as assessed
by a number of symptomatic, global and functional
scales. The primary ﬁndings were improvement in
depressive symptomatology, on both the Bipolar De-
pression Rating Scale (BDRS) and the Montgomery–
A˚sberg Depression Rating Scale (MADRS), with sig-
niﬁcant beneﬁts on functioning and quality of life
also documented (Berk, 2007).
Preclinical studies
In the rat model of mania, pre-treatment with
NAC signiﬁcantly attenuated the methamphetamine-
induced hyperlocomotion, behavioural sensitization,
and striatal dopamine depletion in a dose-dependent
fashion (Fukami et al., 2004).
Depression
There is evidence for oxidative disturbances in major
depression, as demonstrated by oxidative marker
studies and those examining the antioxidant eﬀects
of antidepressants (Table 3). There is no data of anti-
oxidants as therapeutic agents for this condition.
Markers of oxidative disturbances
Animal studies
Data from animal models have demonstrated the de-
pletion of glutathione (Pal and Dandiya, 1994), re-
duction of GSH-Px and vitamin C, and rise in lipid
peroxidation and NO (Eren et al., 2007b) in association
with stress-induced behavioural depression.
Human assays of oxidants, antioxidants and
oxidative products
Human studies have reported a number of oxidative
disturbances in patients with major depression, in-
cluding oxidative damage in erythrocytic membranes
as suggested by the depletion of omega-3 fatty acids
(Peet et al., 1998); elevated lipid peroxidation products
(Bilici et al., 2001; Khanzode et al., 2003; Sarandol
et al., 2007b; Selley, 2004) ; oxidative DNA damage
(Forlenza andMiller, 2006) ; reduced serum vitamins C
(Khanzode et al., 2003) and E (Maes et al., 2000; Owen
et al., 2005), the latter of which was not accounted for
by dietary insuﬃciency (Owen et al., 2005) ; increased
concentrations of the endogenous inhibitor of endo-
thelial NO synthase asymmetric dimethylarginine
(ADMA) (Selley, 2004) and decreased NO (Selley,
2004; Srivastava et al., 2002). Albumin, which has
antioxidant activity, has also been reported to be
compromised in major depression (Van Hunsel et al.,
1996). Findings of altered antioxidant enzyme levels
have been mixed, with reports of elevated SOD (Bilici
et al., 2001; Khanzode et al., 2003; Sarandol et al.,
2007b), GSH-Px and GR (Bilici et al., 2001), diminished
SOD (Herken et al., 2007), and no change (Srivastava
et al., 2002). In one study of major depressive disorder
patients who had been medication-free for at least
2 months, the plasma total antioxidant potential and
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Table 3. Data relating to oxidative stress disturbances in major depressive disorder
Compared with controls Sample size (n) of patients
Markers of oxidative disturbances
Assays of oxidants and antioxidants
NO
metabolites
Plasma Decreased 25 (Selley, 2004)
Serum Unchanged 36 (Herken et al., 2007)
PMN Decreased 30 (Srivastava et al., 2001)




SOD Serum Increased 62 (Khanzode et al., 2003)
Decreased 36 (Herken et al., 2007)
Erythrocyte Increased 12, 18 (Bilici et al., 2001) ; 96
(Sarandol et al., 2007b)
PMN Unchanged 15 (Srivastava et al., 2001)
CAT Erythrocyte Unchanged 12, 18 (Bilici et al., 2001)
PMN Unchanged 26 (Srivastava et al., 2001)
GSH-Px Plasma Unchanged 12, 18 (Bilici et al., 2001)
Erythrocyte Increased 12 (Bilici et al., 2001)
Unchanged 18 (Bilici et al., 2001)
PMN Unchanged 12 (Srivastava et al., 2001)
Vitamin C Plasma Decreased 62 (Khanzode et al., 2003)
Vitamin E Plasma or serum Decreased 42 (Maes et al., 2000) ; 49 (Owen et al., 2005)
Albumin, total
serum protein
Plasma or serum Decreased 37 (Van Hunsel et al., 1996)




Plasma Decreased 21 (Yanik et al., 2004a)
Assays of oxidative products
TBARS/MDA Plasma or serum Increased 12, 18 (Bilici et al., 2001) ; 62 (Khanzode et al.,
2003) ; 96 (Sarandol et al., 2007b)
Erythrocyte Increased 12, 18 (Bilici et al., 2001) ; 96 (Sarandol et al.,
2007b)
HNE Plasma Increased 25 (Selley, 2004)
8-OHdG Serum Increased 84 (Forlenza and Miller, 2006)
Antioxidant properties of antidepressants
Clinical
studies
Improved lipid peroxidation and
antioxidative enzyme levels after
treatment with SSRIs for 3months
30 (Bilici et al., 2001)
Improved MDA, SOD and vitamin C
levels with SSRIs for 3 months
62 (Khanzode et al., 2003)
Improved SOD and NO levels after
antidepressant treatment for 8 wk
36 (Herken et al., 2007)
No signiﬁcant changes in oxidative markers
with 6 wk of antidepressant treatment
96 (Sarandol et al., 2007b)
Preclinical
studies
Mice Replenish glutathione depletion;
prevent and/or reverse shock-
induced behavioural depression
Imipramine, maprotiline, ﬂuvoxamine,
trazodone (Pal and Dandiya, 1994)
Rats Correction of GSH-Px, glutathione,
vitamin C, and lipid peroxidation levels
in the stress-induced depression model
Venlafaxine (Eren et al., 2007b)
Modulation of antioxidant proteins Venlafaxine, ﬂuoxetine (Khawaja et al., 2004)
Improvement of depression-related
lipid peroxidation, and GSH-Px,
glutathione and vitamin C depletion
Lamotrigine, aripiprazole, escitalopram





Moclobemide (Verleye et al., 2007)
Attenuate cell loss from chemical
oxidative stress ; antioxidant eﬀects
Phenelzine (Lee et al., 2003)
8-OhdG, 8-hydroxy-2’-deoxyguanosine; CAT, catalase; GR, glutathione reductase; GSH-Px, glutathione peroxidase ; HNE,
(E)-4-Hydroxy-2-nonenal; MDA, malondialdehyde; NO, nitric oxide; PMN, polymorphonucleocyte ; SOD, superoxide
dismutase ; SSRI, selective serotonin reuptake inhibitor ; TBARS, thiobarbituric acid reactive substances.
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uric acid were reduced in patients compared with
controls, whereas their total plasma peroxide levels
and oxidative stress index were both higher (Yanik
et al., 2004a). Moreover, a signiﬁcant positive corre-
lation was found between oxidative stress index and
the Hamilton Depression Rating Scale (HAMD) (Yanik
et al., 2004a). Similarly, other studies have also re-
ported correlations between depressive severity and
the magnitude of disturbances in their respective
oxidative indices (Bilici et al., 2001; Forlenza and
Miller, 2006; Owen et al., 2005; Sarandol et al., 2007b),
although one study found no such relationship
(Herken et al., 2007).
The enhanced oxidation of apolipoprotein B-
containing lipoproteins, correlating with the severity
of major depression, along with signiﬁcant reductions
in serumparaoxonase/arylesterase activities following
antidepressant treatment, have been demonstrated
(Sarandol et al., 2006). As oxidation of lipoproteins
and low paraoxonase activity have been implicated
in atherogenesis and coronary artery disease, these
results may be relevant in understanding the link be-
tween major depression and cardiovascular disease
(Sarandol et al., 2006). Others have also suggested
oxidative changes, such as cumulative oxidative DNA
damage, to be a common pathophysiological mech-
anism underlying major depression and medical co-
morbidities (Forlenza and Miller, 2006).
Antioxidant properties of antidepressants
Clinical studies
A small group of studies, by demonstrating reversals
of antioxidant and oxidative disturbances after anti-
depressant treatments, has provided evidence for
the antioxidant eﬀects of these drugs (Bilici et al.,
2001; Herken et al., 2007; Khanzode et al., 2003).
Relating to this observation, oxidative parameters
have been nominated by some authors to be candidate
markers of antidepressant eﬃcacy (Bilici et al., 2001;
Herken et al., 2007). However, studies have not
been unanimous in associating normalization of
oxidative parameters with antidepressant treatment.
One comparatively larger study found that 6 wk
of antidepressant treatment did not aﬀect oxidative-
antioxidative systems, regardless of the response
or remission status of the patients (Sarandol et al.,
2007b).
For drugs other than antidepressants, the anti-
oxidant eﬀects of lithium may also lend support
for oxidative stress mechanisms behind major de-
pression, as it has an established role as adjunctive
treatment.
Preclinical studies
In animal studies, antidepressants of diﬀerent classes
have been shown to replenish, to varying degrees, the
glutathione depletion seen in the inescapable shock be-
havioural paradigm of depression (Pal and Dandiya,
1994). Venlafaxine was associated with the correction
of several depression-speciﬁc oxidative markers in the
rat cortex (Eren et al., 2007b). A proteomic study using
rats has found multiple protein modulations in the
hippocampus after venlafaxine or ﬂuoxetine adminis-
tration. Antioxidant and anti-apoptotic proteins were
among those identiﬁed (Khawaja et al., 2004). In
another animal study, lamotrigine, aripiprazole and
escitalopram were all shown to improve depression-
related GSH-Px, glutathione and Vitamin C depletion,
and lipid peroxidation increase. Of the three drugs,
lamotrigine was associated with the greatest anti-
oxidative protective eﬀects (Eren et al., 2007a). An in-
vitro study of rat cerebrocortex neuronal and astroglial
cultures showed that moclobemide could attenuate
cell death induced by anoxia and glutamate, a process
involving oxidative stress pathways (Verleye et al.,
2007). The monoamine oxidase inhibitor phenelzine
was able to attenuate the loss of diﬀerentiated rat
PC12 cells exposed to chemical oxidative stress, and
demonstrated antioxidant eﬀects including the re-
duction of ROS formation and the scavenging of the
pro-oxidant hydrogen peroxide (Lee et al., 2003).
Antioxidant therapies
Preclinical studies
As no clinical trials of antioxidant therapies have been
published for major depressive disorder, the primary
evidence for antioxidant eﬃcacy at present is derived
from the previously cited animal study, which demon-
strated the prevention and reversal of shock-induced
behavioural depression with glutathione (Pal and
Dandiya, 1994).
Indirect clinical studies
A small (n=16), open-label study of adjunctive EGb in
the treatment of patients with major depressive has
been published, reporting positive outcomes in terms
of improved sleep eﬃciency and awakenings, but de-
pressive outcomes were not reported (Hemmeter
et al., 2001). The beneﬁcial eﬀects of NAC on mood in
a non-clinically depressed population have been re-
ported from a double-blind, placebo-controlled study
of NAC in patients with mild chronic bronchitis. NAC
recipients showed signiﬁcantly superior outcomes
on the General Health Questionnaire (GHQ), which
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predominantly measures mood, compared with the
placebo group (Hansen et al., 1994). The limitations to
generalizing these indirect results to depression are
apparent.
Anxiety disorders
The notion of oxidative stress mechanisms underlying
anxiety disorder has been in existence for some years,
with the earlier suggestion that NO and peroxynitrite
might play a major role in setting up a vicious aetio-
logical cycle involving free radicals and inﬂammatory
cytokines in post-traumatic stress disorder (Miller,
1999; Pall and Satterlee, 2001). However, oxidation
biology research in anxiety disorders is still at its in-
fancy, and the bulk of the limited literature originates
from animal studies, which have nevertheless gener-
ated intriguing ﬁndings.
Animal studies
An interesting set of animal experiments have linked
glyoxalase 1 (Glo1) and glutathione reductase 1 (GR)
genes, both of which protect against oxidative stress,
with anxiety in mice (Hovatta et al., 2005). By using
behavioural analysis of six inbred mouse strains to
determine anxiety phenotypes and quantitative gene
expression proﬁling of seven pertinent brain regions,
17 candidate genes were identiﬁed, of which both
Glo1 and GR showed positive correlations between
their expressed activity levels and phenotypic anxiety
status. The causal role that these genes may play in
anxiety were supported by a series of experiments,
which conﬁrmed a highly signiﬁcant positive corre-
lation between the expressed activities of these genes
and anxiety in cross-bred mice, and demonstrated
that over-expression of Glo1 and GR in the cingulate
cortex increased anxiety behaviours, while inhibition
of Glo1 gene expression reduced such behaviours
(Hovatta et al., 2005). The over-expression of Glo1 in
innately anxious mice has also been reported by others
(Landgraf et al., 2007).
Further evidence for oxidative pathways being in-
volved in mouse models of anxiety can be derived
from the association of vitamin E depletion and
increased oxidative stress markers and anxiety
behaviours in phospholipid transfer protein (PLTP)
knock-out mice (Desrumaux et al., 2005), and from a
positive correlation between peripheral blood oxidat-
ive stress markers and anxiety behaviours (Bouayed
et al., 2007b). The pro-oxidative vitamin A has been
demonstrated to induce oxidative stress in the rat
hippocampus, as measured by increased lipid per-
oxidation, protein carbonylation, protein thiol oxida-
tion, and altered SOD and CAT levels, as well as
causing anxiety behaviours in the animal model (de
Oliveira et al., 2007). In addition, green tea polyphenol
(–)-epigallocatechin gallate (EGCG), a potent anti-
oxidant, showed anxiolytic eﬀects on mice with a
dose-dependent relationship (Vignes et al., 2006).
Anxiolytic eﬀects have also been reported in mice
with chlorogenic acid, a dietary polyphenol and anti-
oxidant (Bouayed et al., 2007a). Inconsistent results
have been reported for whortleberry extracts in rats,
and vitamin E was found to increase anxiety in the
same study (Kolosova et al., 2006).
Human studies
In humans, only a handful of relevant studies have
been published. These have reported elevated lipid
peroxidation products and antioxidant changes in
obsessive–compulsive disorder (Ersan et al., 2006;
Kuloglu et al., 2002a), panic disorder (Kuloglu et al.,
2002b) and social phobia (Atmaca et al., 2004), but not
in post-traumatic stress disorder (Tezcan et al., 2003).
The study on social phobia also found a reversal of
these disturbances following 8 wk of citalopram
treatment (Atmaca et al., 2004). A study of anxious
women found reduced total antioxidant capacity
among this group compared with non-anxious
controls, in conjunction with several parameters of
impaired immune functioning (Arranz et al., 2007).
A case series has reported improvement in tricho-
tillomania, pathological nail-biting and skin-picking,
conditions that have similarities with obsessive–
compulsive disorder, using NAC (Odlaug and Grant,
2007).
Substance abuse
Substance abuse and dependence are important to
consider in psychiatric disorders, given the substantial
overlap between the two in terms of syndromal mani-
festations and causality. A solid body of literature
exists in support of the association between oxidative
stress and common drugs of abuse, including nicotine
(Petruzzelli et al., 2000), alcohol (Peng et al., 2005),
cannabis (Saraﬁan et al., 1999), heroin (Pan et al., 2005),
cocaine (Dietrich et al., 2005) and amphetamines (Frey
et al., 2006c). Although their precise roles are yet to be
fully understood, oxidative mechanisms have been
proposed to mediate both the processes of drug ad-
diction and toxicity (Kovacic, 2005; Kovacic and
Cooksy, 2005), and antioxidants may thus have thera-
peutic potential in the management of these condi-
tions. Preclinical evidence has indicated antioxidants
to be promising in alcohol (Amanvermez and Agara,
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2006), heroin (Zhou and Kalivas, 2007) and cocaine
dependence (Baker et al., 2003). Pilot clinical trial data
of NAC in cocaine dependence have been promising,
suggesting that craving and withdrawal symptoms
(LaRowe et al., 2006) as well as cue-evoked desire are
reduced with the administration of NAC (LaRowe
et al., 2007).
Other conditions
A growing literature has been published that cites
evidence for oxidative disturbances in autism, in-
cluding genetic polymorphisms aﬀecting oxidative
metabolic pathways (James et al., 2006), reduced anti-
oxidant capacity (Chauhan et al., 2004; James et al.,
2004, 2006), antioxidant enzyme changes (Sogut et al.,
2003; Yorbik et al., 2002; Zoroglu et al., 2004) and en-
hanced oxidative stress biomarkers (Chauhan et al.,
2004; James et al., 2004; Ming et al., 2005; Sogut et al.,
2003; Yao et al., 2006b; Zoroglu et al., 2004). Impaired
oxidative status has also been reported for ADHD,
and a randomized, controlled trial of Pycnogenol,
a pine bark extract with potent antioxidant pro-
perties, in children diagnosed with ADHD (n=61) has
found symptomatic and biochemical improvements
(Chovanova et al., 2006; Dvorakova et al., 2006;
Trebaticka et al., 2006). On the other hand, a small
(n=24) study comparing Pycnogenol and methyl-
phenidate in adult ADHD has failed to show any ad-
vantage of either treatment over placebo (Tenenbaum
et al., 2002).
Discussion
Currently, the most robust and multi-dimensional
evidence for the pathophysiological involvement of
oxidative stress is for schizophrenia, followed by
bipolar disorder, with both having support from pre-
clinical and clinical research. The data is less extensive
for the other psychiatric disorders, but there is ac-
cumulating evidence indicating a role of oxidative
stress in their aetiopathogenesis. In summary, there is
evidence for glutathione depletion in schizophrenia;
increased lipid peroxidation in schizophrenia, bipolar
and major depressive disorders ; and reduction in
antioxidants such as albumin and bilirubin in schizo-
phrenia and major depressive disorder. Findings in
relation to NO and antioxidative enzymes in these
disorders have been less consistent. Data from mol-
ecular and genetic studies have implicated oxidative
metabolic pathways in the aetiopathogenesis of
schizophrenia, bipolar disorder and possibly an-
xiety disorders. Antipsychotics, mood stabilizers and
antidepressants have all been demonstrated to have
antioxidative eﬀects, and some antioxidants have been
reported to be of therapeutic beneﬁt, including vit-
amins C and E and EGb for schizophrenia, and NAC
for schizophrenia and bipolar disorder.
In the interpretation of mass data, the context and
limitations of each investigation must be borne in
mind. In view of the complexities of psychiatric con-
ditions and biological systems, and the diversity of
research areas, the collective signiﬁcance of study
ﬁndings would be expected to have greater strength
than individual results. For instance, a substantial
portion of the existing evidence base is derived from
the comparison of oxidative biochemical status of
patients with controls, and such studies have yielded
apparently inconsistent results, with varying presence,
directions or combinations of disturbances in markers
of oxidant and antioxidant activities. Such variations
in cross-sectional proﬁles of selected oxidant/anti-
oxidant markers may merely reﬂect their dynamic
status in the wider oxidative biochemical system,
which in turn exists in intricate balance with other
biological pathways and systems. Moreover, psychi-
atric syndromes are aetiologically heterogeneous,
commonly chronic and multiphasic, and often over-
lapping, thus further complicating the speciﬁcity of
individual marker changes. Alternatively, it is possible
that the mixed ﬁndings may signify an indirect
pathophysiological role of the relevant oxidative
markers in the disorders. However, on balance, the
literature as a whole seems to provide suﬃcient con-
sistent evidence that oxidative stress balance is sig-
niﬁcantly altered in patient groups. In particular,
ﬁndings of elevated oxidative products across dis-
orders supply fairly direct evidence of increased
oxidative stress, while its aetiological signiﬁcance is
supported by genetic and molecular studies that link
speciﬁc oxidative pathway polymorphisms or gene
expression to speciﬁc disorders. Genetic manipulation
experiments demonstrating positive correlations be-
tween the expression of speciﬁc oxidative genes
and anxiety behaviours in animal models further
validate this aetiopathogenic hypothesis. However, it
is diﬃcult to distinguish from current data whether
oxidative stress results from primary excessive mito-
chondrial energy generation, primary dysfunction
within oxidative homeostatic mechanisms, or both.
Impaired mitochondrial energy metabolism has also
been suggested to be a fundamental defect in bipolar
disorder (Kato, 2007; Young, 2007), with hypometa-
bolism, energy imbalance and oxidative stress assum-
ing secondary roles, and may present an alternative
hypothesis. In practical terms, pharmacological and
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clinical studies have established the antioxidant
properties of eﬃcacious pharmacotherapies, and anti-
oxidant treatment data, although limited in quantity,
have reported promising therapeutic potentials.
The implications of the expanding data on oxidative
stress mechanisms in psychiatric disorders are two-
fold, having salience in both furthering their aetio-
pathogenic understanding and treatment options.
In relation to the former, the aetiopathogenic mech-
anisms for psychiatric disorders remain largely elus-
ive, despite the growth of hypotheses on multiple
conceptual levels that include sociocultural systems,
personality, cognitive schemata, behavioural learning,
neuroanatomy, psychoneuroendoimmunology, bio-
molecules and genetics. Given the complexities of
human psychobehavioural systems and the inﬁnite
deterministic variability behind their manifestations,
basic biopathway pathologies may present tangible
and widely applicable pathophysiological models, as
all psychobehavioural manifestations must have fun-
damental biological underpinnings. There is gathering
evidence for oxidative stress to be one such biopath-
way, as oxidative damage is believed to be a major
mechanism underlying cell dysfunction and death
in both ageing and disease processes, although its
temporal role in and relative contribution to these
processes is likely to vary. Theoretically, oxidative
stress may result from the overproduction of free
radicals, defective oxidative homeostasis, or a combi-
nation of both. Each of these situations, in turn, is
likely to stem from diﬀerent causes, which may in-
clude overactive oxidative metabolism driven by
physiological stress, pathogens or the inﬂammatory
response, genetic polymorphisms and physiological
factors that undermine the oxidative defence capacity
of the individual, and diﬀerential expression of mito-
chondrial and metabolic enzymes. Once established,
secondary ampliﬁcations or self-perpetuating oxidat-
ive cascades may also play a role in the pathogenesis
of illnesses, the continuation of symptoms and vul-
nerability to future illness relapses.
Evidence for the interdependent relationships be-
tween oxidative pathways and those involving neuro-
transmitters, hormones and inﬂammatory mediators
further enhance the plausibility of the oxidative stress
hypothesis, and provide a unifying framework for
the various conceptual theories of causality. Dopa-
minergic, noradrenergic and glutamatergic over-
activity have been demonstrated to induce cytotoxicity
via oxidative stress among other mechanisms (Chan
et al., 2007; Chen et al., 2003; Penugonda et al., 2005),
and this cytotoxicity has been suggested to be speciﬁc
for neurones (Chan et al., 2007). There is also evidence
for a link between neuro-inﬂammatory processes and
oxidative stress, which may be mediated by the over-
production of free radicals by activated glial cells
during inﬂammatory states, and/or via the activation
of the cyclooxygenase (COX) and lipoxygenase (LOX)
pathways or pro-inﬂammatory cytokines such as
tumour necrosis factor-a (TNF-a), interleukin-1 and
interferon-c (Hayley et al., 2005; Tansey et al., 2007).
These connections provide a basis for explaining
phenomena such as drug-induced and organic psy-
chiatric syndromes, as well as comorbid somatic and
psychiatric disorders. The association of particular
neurochemical pathways with oxidative stress induc-
tion, combined with the diﬀering vulnerabilities of
neuronal and glial cells to oxidative damage according
to their types and anatomical positions, may help to
explain the involvement of speciﬁc neurological sites
in psychiatric syndromes. This speciﬁcity of site can be
observed in neuroimaging studies (Ettinger et al.,
2007; Sheline et al., 2003; van Erp et al., 2004), and
may be useful in attempting to understand both
the acute and long-term syndromal manifestations
of the various psychiatric conditions. The involvement
of similar sites across conditions may also account
for their symptomatic overlap and diagnostic muta-
bility.
Apart from conceptual utility, a theory of value
should also demonstrate practical applicability. An
appealing aspect of the oxidative stress theory is that
regardless of the precise defect(s), this state of dis-
equilibrium can theoretically be corrected by bolster-
ing the total antioxidant capacity, providing that the
supplementary antioxidants are bioactive and able to
access the brain. The practical utility of this theory has
already garnered support from the existing literature,
which has found beneﬁts from the use of vitamins C
and E, EGb, NAC and other antioxidants in psychiatric
disorders. NAC, in particular, seems to hold the most
promising evidence for eﬃcacy across diagnoses, with
beneﬁts recently reported for schizophrenia, bipolar
disorder, cocaine dependence, and impulsive control
disorders. This may relate to its bioavailability and
putative mechanisms of replenishing and enhancing
glutathione stores (Dean et al., 2004), which possibly
has a more weighted impact in the brain than other
antioxidants. Further clinical evidence is required to
consolidate the eﬃcacies of antioxidants for the vari-
ous conditions, but their potential in acute and main-
tenance treatment settings are clearly implied on
theoretical grounds. Furthermore, these treatments
may be useful in the prevention of long-term sequelae
by minimizing cell damage and cell death, as well
as primary prevention in vulnerable individuals.
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These treatments are generally associated with low
occurrence of side-eﬀects, which is an attractive fea-
ture conducive to long-term treatment adherence.
The investigation of antioxidants in psychiatric
disorders has perhaps been hampered by several un-
favourable factors, the main ones probably relating
to the conventional aetiopathophysiological under-
standing of psychiatric disorders and to misconcep-
tions about antioxidants. Traditionally, psychiatric
teachings and research have focused on neuro-
transmitter aetiological theories, such as the dopamine
theory for schizophrenia and the monoamine hypoth-
esis for depression, and these have provided a basis
for therapeutic manipulations. Entwined with this
situation is the fact that the majority of established
biological treatments, where their mechanisms of ac-
tion are clariﬁed, have primary discernible eﬀects on
neurotransmitter receptors and/or their biodegra-
dation. Antioxidants serve a buﬀering role in oxidative
physiology, and are often regarded as ‘natural ’ rem-
edies rather than pharmacological therapies. How-
ever, the usefulness of precursor compounds to
‘natural ’ endogenous substances is not unfamiliar in
medicine, as exempliﬁed by L-dopa in the treatment of
Parkinson disease, a drug which can be analogously
compared with the cysteine precursor, NAC. The un-
familiar mechanisms of action of antioxidants to clini-
cal psychiatry may thus have contributed to their
peripheral therapeutic status. Furthermore, the hetero-
geneity within antioxidants as a class is not widely
appreciated. Diﬀerences exist among the antioxidants
in their targets of action, as well as in their pharma-
cokinetic properties. Vitamin E, for example, has a
principal antioxidant action of scavenging peroxyl
radicals in biological lipid phases (Traber and
Atkinson, 2007), in addition to multiple non-
antioxidant properties that include modulation of
signal transduction, transcriptional and translational
processes (Zingg and Azzi, 2004), yet its antioxidant
eﬃcacy in pathological redox states has not been
established (Azzi, 2007). Vitamin C, on the other
hand, is a scavenger of free radicals in water phases
(Rodrigo et al., 2007), while Ginkgo biloba has anti-
oxidant properties that probably include the preven-
tion of lipid peroxidation (Drieu et al., 2000). The
speciﬁc antioxidant actions of these agents, when
applied to neuropsychiatric conditions where the
precise oxidative defects are not yet clear, may account
for some ineﬃcacious trial ﬁndings (Boothby and
Doering, 2005). In this respect, glutathione may be the
most generic of cellular antioxidants in terms of its
molecular actions, which may explain the promising
ﬁndings with NAC.
Besides pharmacological treatments, lifestyle and
dietary manipulations are relevant in optimizing oxi-
dative balance. A diet rich in natural antioxidants and
the avoidance of oxidative stress-inducing habits such
as cigarette smoking and substance abuse are prudent
measures. Diets high in saturated fats may increase
oxidative stress (Shih et al., 2007), and their intake are
best minimized. Physical exercise, speciﬁcally endur-
ance training, has also been suggested to have a ben-
eﬁcial impact on oxidative stress status, possibly
mediated by increasing total antioxidant capacity and
GSH-Px activity (Fatouros et al., 2004).
The other major practical implication ensuing
from the oxidative stress theory of pathogenesis is the
potential use of oxidative/antioxidant proﬁles and
oxidative products as biomarkers of psychiatric dis-
orders, their activity status and treatment response.
Although the current state of evidence is not yet ma-
ture enough to adopt this in clinical practice, ﬁndings
of syndrome- (Reddy et al., 2003) and phase-speciﬁc
(Andreazza et al., 2007) proﬁles, and treatment-related
normalization (Bilici et al., 2001; Dakhale et al., 2004;
Frey et al., 2007; Gergerlioglu et al., 2007; Henneman
and Altschule, 1951; Herken et al., 2007; Khanzode
et al., 2003; Ozcan et al., 2004; Zhang et al., 2003)
support this as a possible future application. Genetic
polymorphisms of antioxidant enzymes, associated
with psychiatric disorders (Akyol et al., 2005; Saadat
et al., 2007; Tosic et al., 2006), may have potential in
assisting the identiﬁcation of at-risk individuals.
In research, broad areas remain to be explored on
both preclinical and clinical levels, especially for mood
and anxiety disorders which have an early evidence
base. The use of antioxidants in their treatment is both
substantiated and promising, in view of the internally
consistent theoretical framework, convincing early
evidence, wide-ranging potential therapeutic beneﬁts,
the high population prevalence and overall disease
burden associated with these disorders, and the lim-
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